Caredx reports inducement grants under nasdaq listing rule 5635(c)(4)

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with caredx, on september 12, 2024, 14 new employees were awarded restricted stock units (rsus) for an aggregate of 44,000 shares o.
CDNA Ratings Summary
CDNA Quant Ranking